# How Long Ipamorelin Stays in Your System: Half-Life and Clearance > How long does ipamorelin stay in your system? Terminal half-life is about 2 hours in humans, with clearance 0.078 L/h/kg. The full elimination profile, cited. The terminal half-life, the clearance, the volume of distribution, and how the GH pulse outlasts the molecule — every constant cited. ## The short answer If you want to know how long does ipamorelin stay in your system, the human data gives a clean number: a terminal half-life of about 2 hours [2]. Half-life is the time it takes for the amount in your blood to drop by half. After one half-life roughly half is gone; after about five half-lives — here, around 10 hours — the peptide is essentially cleared from the bloodstream. The peptide itself is short-lived. The interesting twist is that its main effect outlasts it: the growth-hormone pulse ipamorelin triggers peaks about 40 minutes after the dose, then the hormone follows its own decay, so the biological 'shadow' of a dose runs a little longer than the molecule's own clearance [2]. The numbers below come from the one human pharmacokinetic study and a supporting rat study. ## The human elimination constants The defining dataset modeled pharmacokinetics in healthy male volunteers, eight per dose level, given five 15-minute intravenous infusions from 4.21 to 140.45 nmol/kg [2]. Three constants describe the elimination. The terminal half-life is approximately 2 hours [2]. Clearance — the volume of blood cleared of the peptide per unit time — is 0.078 L/h/kg [2]. The steady-state volume of distribution is 0.22 L/kg, which is small and tells you the peptide stays mostly in the bloodstream and does not diffuse deeply into body tissues [2]. Because the kinetics were dose-proportional across a more than 30-fold dose range, these constants hold whether the dose is small or large — the system is linear, not saturable, in the range tested [2]. ## Why the GH pulse and the half-life are different clocks A common confusion is treating 'how long ipamorelin lasts' and 'how long the growth-hormone burst lasts' as the same question. They are two clocks. Ipamorelin's own half-life is about 2 hours [2]. But its job is to set off a single discrete pulse of growth hormone, and that pulse peaks at roughly 0.67 hours — 40 minutes — after dosing, then declines on growth hormone's own schedule [2]. So the molecule can be largely cleared while the downstream hormone signal is still resolving. This two-clock behavior is the practical reason the pharmacokinetics are reported alongside the pharmacodynamics in the same human study, rather than separately [2]. ## What the animal data adds about clearance Rodent pharmacokinetics fill in the metabolic-stability picture behind the human half-life. In male rats, ipamorelin's plasma clearance was roughly five-fold lower than GHRP-6, and 60-80% of the dose was recovered intact in bile and urine, indicating moderate metabolic stability rather than rapid destruction [7]. The same work measured an intranasal bioavailability of about 20% [7]. The structural reason for the slow clearance is built into the sequence: the non-natural alpha-aminoisobutyric acid at position 1 and the D-amino acids resist the enzymes that would otherwise chop a peptide apart [1]. The throughline from rat to human is consistent — a peptide engineered for stability, with a short but well-defined and predictable elimination profile. ## Detection and the anti-doping angle Although the peptide clears the bloodstream within hours, its use is detectable for anti-doping purposes through urinary metabolites. Analytical work has determined growth-hormone-releasing-peptide metabolites in human urine after nasal administration, underpinning the detection methods used to screen for GHRPs — directly relevant to ipamorelin's status as a WADA-prohibited substance with established urinary detection [8]. In other words, 'cleared from blood in hours' and 'detectable in a doping test' are not contradictory: the parent peptide's short half-life governs the first, while metabolite-based urine assays govern the second [8]. Ipamorelin is prohibited in sport at all times under WADA category S2 [8]. ## How the diabetic state changes the picture The half-life describes how fast the peptide leaves; it does not capture how the body's metabolic state can change the *response* to a given exposure. A streptozotocin-diabetic mouse study makes this concrete: intravenous ipamorelin produced significantly greater growth-hormone hypersecretion in diabetic animals (150 +/- 35 microg/L) than in non-diabetic controls (62 +/- 11 microg/L), alongside hepatic growth-hormone-receptor resistance and suppressed IGF-1 [9]. The lesson for any 'how long does it stay in your system' question is that pharmacokinetics (how the body handles the drug) and pharmacodynamics (what the drug does to the body) are separate, and the second can shift with underlying physiology even when the first is fixed. The human half-life data come from healthy male volunteers [2]; how those constants and the downstream growth-hormone response behave in people with metabolic disease has not been characterized in humans. In short, the two-hour figure is a clean, well-supported answer to how long the molecule itself persists, but it is the beginning of the story rather than the whole of it: the downstream growth-hormone pulse, the metabolic context, and the route of administration all shape what that cleared-in-hours number means in practice [2]. --- A telemetry-grade reading of the published ipamorelin record — the half-life, the clearance, and the single growth-hormone pulse logged and cited; no clinic behind the console and nothing here dosed, dispensed, or sold.